Intervacc (OM:IVACC) - Cotización, noticias y análisis

Resumen de acción IVACC

Intervacc AB (publ) desarrolla en Suecia nuevas vacunas veterinarias para animales. Saber más

Análisis fundamental de IVACC
Puntuación del snowflake
Valoración	1/6
Crecimiento futuro	2/6
Rendimiento pasado	0/6
Salud financiera	5/6
Dividendos	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 104.86%

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares (SEK9M)

Tiene menos de 1 año de cash runway

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

No tiene una capitalización de mercado significativa (SEK197M)

+ 1 riesgos adicionales

Competidores de Intervacc AB (publ)

Alzinova

OM:ALZ

SEK 331.7m

Biovica International

OM:BIOVIC B

SEK 168.8m

AcouSort

OM:ACOU

SEK 173.2m

Toleranzia

OM:TOL

SEK 112.3m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Intervacc
Precios históricos de las acciones
Precio actual de la acción	SEK 2.66
Máximo en las últimas 52 semanas	SEK 10.46
Mínimo de 52 semanas	SEK 2.00
Beta	0.62
1Cambio en 1 mes	-5.67%
Variación en 3 meses	-38.14%
Cambio de 1 año	-58.57%
3Variación en 3 años	-95.73%
Variación en 5 años	-87.33%
Variación desde la OPV	-65.45%

Noticias y actualizaciones recientes

Is Intervacc (STO:IVACC) In A Good Position To Invest In Growth?

Jun 08

Recent updates

Here's Why We're Not At All Concerned With Intervacc's (STO:IVACC) Cash Burn Situation

Dec 15

It Looks Like The CEO Of Intervacc AB (publ) (STO:IVACC) May Be Underpaid Compared To Peers

Jun 01

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

May 17

Intervacc AB (publ) (STO:IVACC) Insiders Have Been Selling

Feb 28

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

Feb 01

When Will Intervacc AB (publ) (STO:IVACC) Become Profitable?

Jan 06

Is Intervacc AB (publ)'s (STO:IVACC) Shareholder Ownership Skewed Towards Insiders?

Dec 10

Rentabilidad de los accionistas

	IVACC	SE Biotechs	Mercado SE
7D	2.3%	-0.4%	0.1%
1Y	-58.6%	15.1%	11.8%

Rentabilidad vs. Industria: Los resultados de IVACC fueron inferiores a los de la industria Swedish Biotechs, que obtuvo un rendimiento del 15.1% el año pasado.

Rentabilidad vs. Mercado: IVACC obtuvo unos resultados inferiores a los del mercado Swedish, que fueron del 11.8% el año pasado.

Volatilidad de los precios

Is IVACC's price volatile compared to industry and market?
IVACC volatility
IVACC Average Weekly Movement	10.7%
Biotechs Industry Average Movement	9.3%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.2%
10% least volatile stocks in SE Market	3.3%

Precio estable de las acciones: El precio de las acciones de IVACC ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de IVACC(11%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de Swedish.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1983	15	Jonas Sohlman	www.intervacc.se

Intervacc AB (publ) desarrolla en Suecia nuevas vacunas veterinarias para animales. La cartera de productos de la empresa incluye Stangvac, una vacuna contra el estrangulamiento equino para caballos; INV274, antígenos para una vacuna contra Strep. suis para el tratamiento de lechones; e INV412, una vacuna multicomponente para proteger contra varias bacterias que causan mastitis para el tratamiento de vacas.

Resumen de fundamentos de Intervacc AB (publ)

¿Cómo se comparan los beneficios e ingresos de Intervacc con su capitalización de mercado?
Estadísticas fundamentales de IVACC
Capitalización bursátil	SEK 196.91m
Beneficios(TTM)	-SEK 77.34m
Ingresos (TTM)	SEK 9.29m

21.7x

Ratio precio-ventas (PS)

-2.6x

Ratio precio-beneficio (PE)

¿Está IVACC sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de IVACC
Ingresos	SEK 9.29m
Coste de los ingresos	SEK 13.28m
Beneficio bruto	-SEK 3.99m
Otros gastos	SEK 73.34m
Beneficios	-SEK 77.34m

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

Feb 13, 2025

Beneficios por acción (BPA)	-1.02
Margen bruto	-43.01%
Margen de beneficio neto	-832.82%
Ratio deuda/patrimonio	0.06%

¿Cómo se ha desempeñado IVACC a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción IVACC

Recompensas

Análisis de riesgos

Competidores de Intervacc AB (publ)

OM:ALZ

SEK 331.7m

OM:BIOVIC B

SEK 168.8m

OM:ACOU

SEK 173.2m

OM:TOL

SEK 112.3m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.63 loss in 3Q 2023)

Second quarter 2024 earnings released: kr0.24 loss per share (vs kr0.32 loss in 2Q 2023)

Is Intervacc (STO:IVACC) In A Good Position To Invest In Growth?

First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.35 loss in 1Q 2023)

Intervacc AB (Publ) Announces Board Appointments

Intervacc AB (publ) Announces Changes in the Nomination Committee

Recent updates

Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.63 loss in 3Q 2023)

Second quarter 2024 earnings released: kr0.24 loss per share (vs kr0.32 loss in 2Q 2023)

Is Intervacc (STO:IVACC) In A Good Position To Invest In Growth?

First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.35 loss in 1Q 2023)

Intervacc AB (Publ) Announces Board Appointments

Intervacc AB (publ) Announces Changes in the Nomination Committee

Jonas Sohlman Appoints as New CEO for Intervacc AB (publ)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Intervacc AB (publ) to Report Q1, 2024 Results on May 23, 2024

Intervacc AB (publ) Announces Changes in the Nomination Committee

No independent directors

Intervacc AB (publ) Announces Executive Changes

New major risk - Share price stability

Third quarter 2023 earnings released: kr0.78 loss per share (vs kr0.29 loss in 3Q 2022)

Intervacc AB (publ) Announces Composition of Nomination Committee

We're Keeping An Eye On Intervacc's (STO:IVACC) Cash Burn Rate

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr0.31 loss in 2Q 2022)

Intervacc AB (publ) Announces Executive Changes

Intervacc AB (publ) Receives Grant to Optimise Production Processes for A Fusion Protein from Vinnova

Intervacc AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 103.506226 million.

Intervacc AB (Publ) Approves the Election of Boel Sundvall as Board Member

The European Medicines Agency Approves Extention of Shelf Life for Strangvac, Vaccine Against Equine Strangvac, to 33 Months

Veterinary Medicines Directorate (VMD) Extends the Shelf Life for Intervacc AB (publ)'s Strangvac, a Vaccine Against Equine Strangvac, to 33 Months

First quarter 2023 earnings released: kr0.35 loss per share (vs kr0.21 loss in 1Q 2022)

Forecast breakeven date pushed back to 2025

We Think Intervacc (STO:IVACC) Needs To Drive Business Growth Carefully

Full year 2022 earnings released: kr1.28 loss per share (vs kr0.59 loss in FY 2021)

Forecast breakeven date pushed back to 2024

Intervacc AB (publ) to Report Fiscal Year 2022 Results on Apr 06, 2023

Intervacc AB (Publ) Announces Strangvac, A Vaccine Against Equine Strangles Released for Sales in Italy

Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)

Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)

Intervacc AB (Publ) Announces First Batch of Strangvac for Sale in Germany, France, Austria, Belgium, Luxemburg and the Netherlands Released

We're Not Very Worried About Intervacc's (STO:IVACC) Cash Burn Rate

Second quarter 2022 earnings released: kr0.31 loss per share (vs kr0.12 loss in 2Q 2021)

Intervacc AB (Publ) Announces That Strangvac Is Now Available for Sale in the Uk

Intervacc AB (Publ) Elects Michela De Carli as Board Member At the Annual General Meeting Held on June 14, 2022

Intervacc Announces Strangvac, A Vaccine Against Equine Strangles, Available for Sale in Denmark

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Intervacc AB (publ) Announces Initiation of a Proof-Of-Concept Study to Measure the Effectiveness of a Vaccine to Protect Dairy Cows Against Mastitis

We're Not Worried About Intervacc's (STO:IVACC) Cash Burn

Ntervacc AB (Publ) Announces Positive Results from A Proof-Of-Concept Study to Develop A Vaccine Against Streptococcus Suis Infection in Pigs

Full year 2021 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Intervacc AB (publ), Annual General Meeting, Jun 14, 2022

Intervacc Applies for A Permit for Sale and Distribution of Strangvac in the U.S

Intervacc Applies for Supplementary Protection Certificates for Strangvac in Key European Markets

Here's Why We're Not At All Concerned With Intervacc's (STO:IVACC) Cash Burn Situation

Third quarter 2021 earnings released: kr0.17 loss per share (vs kr0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.12 loss per share (vs kr0.13 loss in 2Q 2020)

Intervacc Receives Confirmation of a Positive Outcome for Strangvac, a Vaccine against Equine Strangles, from the VMD in the UK

Intervacc AB Receives Positive CVMP Opinion for Strangvac, A Vaccine Against Equine Strangles, in the EU

Independent Director Newton Aguiar has left the company

It Looks Like The CEO Of Intervacc AB (publ) (STO:IVACC) May Be Underpaid Compared To Peers

First quarter 2021 earnings released: kr0.13 loss per share (vs kr0.15 loss in 1Q 2020)

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

Independent Director recently sold kr29m worth of stock

Intervacc AB (publ) (STO:IVACC) Insiders Have Been Selling